The M-ACCEL trial is a phase IIa study that evaluated the investigational oral drug HU6 for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). This trial aimed to assess the drug's efficacy in reducing liver fat and its impact on body composition over a 26-week treatment period.
The M-ACCEL trial is a phase IIa study that evaluated the investigational oral drug HU6 for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). This trial aimed to assess the drug's efficacy in reducing liver fat and its impact on body composition over a 26-week treatment period. HU6 was tested in three daily doses: 150 mg, 300 mg, and 450 mg, alongside a placebo group for comparison.
The trial demonstrated that HU6 significantly reduced liver fat in patients with MASH. Patients receiving HU6 experienced reductions in liver fat content of 29.4%, 31.2%, and 27% for the 150 mg, 300 mg, and 450 mg doses, respectively, compared to only 6.7% in the placebo group—a statistically significant difference (P=0.005). More than half of the patients on HU6 achieved at least a 30% reduction in liver fat, far exceeding the 22% response rate in the placebo group. Importantly, these reductions occurred without loss of skeletal muscle mass, which is critical for managing weight-related liver diseases.
Additionally, HU6 impacted body composition, with the 450-mg dose leading to significant fat loss (–2.4 kg) compared to placebo (–0.9 kg). Muscle mass remained stable across all HU6 groups. HU6 functions as a controlled metabolic accelerator, increasing mitochondrial energy usage, and offers a promising oral treatment option for MASH with mild side effects and good safety profiles.
Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the interconnected relationship between obesity, type 2 diabetes, chronic kidney disease (CKD), and cardiovascular disease (CVD). These first multidisciplinary guidelines from the AHA, ACC, ADA, and American Society of Nephrology...
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD), obesity, and type 2 diabetes (T2D) represent interconnected global epidemics that frequently coexist and amplify one another. Together, they accelerate liver disease progression, increase cardiometabolic complications, and substantially...
Introduction: Chronic hepatitis B (CHB), hepatic steatosis, and type 2 diabetes mellitus (T2DM) frequently coexist, creating a growing clinical challenge. This multinational study evaluated whether T2DM independently influences liver histology in treatment-naïve CHB patients with...
Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) remains a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma, with limited treatment options. This study evaluated DT-109, a novel glycine-based tripeptide, as a gut-targeted therapy aimed at restoring...
Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) remains a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma, with limited treatment options. This study evaluated DT-109, a novel glycine-based tripeptide, as a gut-targeted therapy aimed at restoring...
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to obesity, diabetes, and cardiovascular disease. While both tirzepatide and SGLT2 inhibitors improve metabolic health, comparative real-world data on long-term liver and cardiovascular outcomes have...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.